Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome - Takeaways - MDSpire

Clinical Insights: The Use of Tocilizumab in Treating Pediatric Febrile Infection-Related Epilepsy Syndrome

  • By

  • Lingyu Pang

  • Xuefang Liu

  • Suzhen Sun

  • Fang Chen

  • Hongru Lu

  • Yakun Du

  • Xin Li

  • June 3, 2026

Share

  • 1

    Tocilizumab is an IL-6 receptor inhibitor showing potential in treating pediatric Febrile Infection-Related Epilepsy Syndrome (FIRES).

  • 2

    Two pediatric patients with FIRES were treated with tocilizumab, with varying outcomes in seizure control and cognitive function.

  • 3

    Early administration of tocilizumab, ideally within three weeks of disease onset, may improve treatment outcomes in FIRES.

  • 4

    Elevated IL-6 levels were noted in the blood and cerebrospinal fluid of patients, indicating a possible autoimmune component in FIRES.

  • 5

    The study highlights the need for further research on tocilizumab's efficacy in pediatric patients with FIRES.

Original Source(s)

Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome

  • by Lingyu Pang, Xuefang Liu, Suzhen Sun, Fang Chen, Hongru Lu, Yakun Du, Xin Li

  • June 3, 2026

Related Content

Neonatal status epilepticus: critical issues in clinical practice

“Do It by Myself” or Autonomy, Participation, and Assistive Devices and Technology Needs of Children and Youth With Disabilities: Text Mining Analysis of a National Survey in France

Effects of ketogenic diet therapy in outpatient anti epileptic drug cost reduction and parental satisfaction among children with intractable epilepsy